
Siwa Biotech Corporation Profile last edited on: 11/18/13
CAGE: 4F4K5
UEI:
Business Identifier: Development of male non-hormonal contraceptive pill Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
755 Research Parkway Suite 125
Oklahoma City, OK 73104
Oklahoma City, OK 73104
(405) 290-7305 |
N/A |
N/A |
Location: Single
Congr. District: 05
County: Oklahoma
Congr. District: 05
County: Oklahoma
Public Profile
Siwa Biotech Corporation has developed technology leading toward a male non-hormonal "pill" form of contraception based on finding an inhibitor for the TPST 2 enzyme, which in animal models renders males infertile without any other side effects. Siwa Biotech Corporation is a spin-off from NovaZyme which was acquired by Genzyme. The spin-off is seeking to exploit its extensive portfolio of issued patents and proprietary knowledge about protein-tyrosine sulfation in order to develop treatments for serious diseases. Siwa is investigating the modulation of protein-tyrosine sulfation to treat a variety of diseases with unmet medical needs. In late 2007, ChemDiv, Inc., a leading chemistry-driven global contract research organization announced signing of a collaborative discovery research agreement with Siwa Biotech Corporation, Oklahoma City, OK. Under the agreement, ChemDiv will be initiating a high-throughput screen for small molecule inhibitors of tyrosylprotein sulfotransferases. The collaboration provides Siwa Biotech with access to ChemDiv's expertise in chemistry systems and lead discovery.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
1-4Revenue Range
Less than .5MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
1-4Awards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2008 | 1 | NIH | $146,456 | |
Project Title: Development Of Tpst Inhibitors As Non-Hormonal Male Contraceptives |
Key People / Management
Kevin L Moore -- President
Penny M Johnson
Penny M Johnson